Ocena trafności histologicznych rozpoznań guzów wewnątrzczaszkowych przez neuroradiologów w oparciu o badanie metodą tomografii komputerowej i rezonansu magnetycznego

Background: Management of patients with intracranial tumor depends on accurate diagnosis of its histology. The aim of this study was to identify the accuracy with which radiologists were able to diagnose the tumor type on CT or MRI. Material/ Methods: Two groups of patients with definitive histopathological diagnoses and with complete radiological documentation were included into the study. The first group contained 85 of 110 patients operated on because of posterior cranial fossa tumor between Jan. 1, 2001, and Feb. 30, 2003. The second group comprised 63 of 100 patients operated on because of supratentorial tumor between Jan. 1 and June 30, 2002. Cases with multiple cerebral metestases or recurrent brain tumors were excluded. Accuracy, sensitivity, and specificity were calculated. Results: In the first group the histological diagnoses were as follows: 25 neurilemmomas, 19 metastases, 16 meningiomas, 10 hemangioblastomas, 7 gliomas, and in the remaining 8 other types. The sensitivities of the radiological diagnoses for the above-mentioned histological types were, respectively, 92%, 89%, 81%, 70%, 86%, and 25%. The general accuracy was 80%. In the second group, 19 were high-grade gliomas, 16 meningiomas, 10 metastases, 7 low-grade gliomas, 7 hypophyseal adenomas, and the remaining 4 were others. The sensitivities of radiological diagnoses were, respectively, 84%, 100%, 70%, 57%, 86%, and 50%. The general accuracy was 81%. Conclusions: CT with contrast, supplemented by MRI in more difficult cases, has high histological diagnostic sensitivity i

Medulloblastoma in adults. A case presentation and review of the literature

AimThe aim of this article is to present a case of medulloblastoma in an adult patient aged 46 and the problems associated with its treatment.Case DescriptionThe authors present a case of medulloblastoma in a 46-year old male patient. The tumour, which is typically identified in childhood, is very rare in adults. The incidence rate, in individuals older than 16 years of age, is 0.05 per 100,000.ResultsThe patient was subjected to combined therapy consisting of surgery and subsequent radiotherapy. This choice of management was successful – the patient has been followed up since the completion of therapy and no relapses have been noted.ConclusionsBased on this particular case, and the current literature, the authors discuss contemporary management methods in medulloblastoma

Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019

Liczba chorych na szpiczaka plazmocytowego zwiększa się, co jest skutkiem zarówno skuteczniejszej diagnostyki, jak również istotnego przedłużania przeżycia chorych. Zawdzięczamy to dostępności nowych leków w pierwszej i kolejnych liniach leczenia, zmianie koncepcji leczenia i przedłużaniu czasu trwania leczenia, stosując leczenie konsolidujące oraz podtrzymujące do progresji choroby. Poza zmianą koncepcji leczenia, zmienia się obecnie również kryterium czasu rozpoczęcia terapii uwzględniające biomarkery aktywności choroby oraz dużą uwagę przywiązuje się optymalizacji leczenia w oparciu o dowody pochodzące z badań klinicznych. W artykule tym przedstawiono także zalecenia dotyczące rozpoznania i leczenia makroglobulinemii Waldenströma i innych dyskrazji plazmocytowych

Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015

New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. Therapeutic regimens based on bortezomib, thalidomide and lenalidomide are recommended to most patients in first line therapy. Induction therapy should be accompanied with prolonged treatment composed of consolidation and maintenance. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease as well as transplantation procedure offered to older, fit patients. In this article we also described therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias

Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017

New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first line therapy, lenalidomide represents the cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance treatment till progression. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described therapeutic recommendation also for Waldenström macroglobulinemia and other plasmacytic dyscrasias

Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2016

New drugs introduced in recent years for the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first-line therapy, lenalidomide represents a cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance or treatment till progression. Beside concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described also therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias